other names
{{ Info.Overview }}
Revenue {{ Info.Revenue | formatUSD }}
Headquarters {{ Info.Headquarters }}

Adviser Profile

As of Date 03/28/2024
Adviser Type - Large advisory firm
Number of Employees 9
of those in investment advisory functions 9
Registration SEC, Approved, 4/9/2014

Client Types

- Pooled investment vehicles

Advisory Activities

- Portfolio management for pooled investment vehicles

Compensation Arrangments

- A percentage of assets under your management
- Performance-based fees

Recent News

Reported AUM

Discretionary
Non-discretionary
2B 2B 2B 1B 1B 691M 345M
2015 2016 2017 2018 2019 2020 2021 2022 2023

Private Funds



Employees

Private Funds Structure

Fund Type Count GAV
Fund TypeHedge Fund Count1 GAV$1,526,579,261
Fund TypePrivate Equity Fund Count7 GAV$1,364,922,071

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM #Funds
Adviser OBERLAND CAPITAL MANAGEMENT LLC Hedge Fund6.0m Liquidity Fund- Private Equity Fund3.1b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV3.1b AUM3.1b #Funds8
Adviser TEKNE CAPITAL MANAGEMENT, LLC Hedge Fund510.0m Liquidity Fund- Private Equity Fund546.3m Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV1.1b AUM1.1b #Funds15
Adviser SOFTVEST ADVISORS Hedge Fund473.6m Liquidity Fund- Private Equity Fund54.7m Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV528.3m AUM544.2m #Funds6
Adviser VECTOR CAPITAL MANAGEMENT, L.P. Hedge Fund512.9m Liquidity Fund- Private Equity Fund3.5b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV4.0b AUM4.1b #Funds8
Adviser SUN CAPITAL ADVISORS, L.P. Hedge Fund15.7m Liquidity Fund- Private Equity Fund6.6b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV6.6b AUM6.6b #Funds15
Adviser CORSAIR CAPITAL LLC Hedge Fund1.2b Liquidity Fund- Private Equity Fund5.1b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV6.2b AUM8.4b #Funds47
Adviser RRG CAPITAL MANAGEMENT LLC Hedge Fund296.7m Liquidity Fund- Private Equity Fund1.5b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV1.8b AUM2.5b #Funds8
Adviser SAGEVIEW CAPITAL LP Hedge Fund19.5m Liquidity Fund- Private Equity Fund1.6b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV1.6b AUM2.1b #Funds7
Adviser GRATUS CAPITAL, LLC Hedge Fund19.2m Liquidity Fund- Private Equity Fund141.0m Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV160.1m AUM2.7b #Funds7
Adviser BURFORD CAPITAL INVESTMENT MANAGEMENT LLC Hedge Fund- Liquidity Fund- Private Equity Fund3.4b Real Estate Fund- Securitized Asset Fund- Venture Capital Fund- Other Fund- Total Private Fund GAV3.4b AUM3.4b #Funds12

Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
Stck Ticker03770N101 Stock NameAPOGEE THERAPEUTICS INC $ Position$334,212,181 % Position21.00% $ Change-41.00% # Change0.00%
Stck Ticker35104E100 Stock Name4D MOLECULAR THERAPEUTICS IN $ Position$92,356,000 % Position6.00% $ Change-34.00% # Change0.00%
Stck Ticker29337E102 Stock NameENLIVEN THERAPEUTICS INC $ Position$94,095,355 % Position6.00% $ Change33.00% # Change0.00%
Stck Ticker67576A100 Stock NameOCULAR THERAPEUTIX INC $ Position$87,295,240 % Position6.00% $ Change-25.00% # Change0.00%
Stck Ticker483497103 Stock NameKALVISTA PHARMACEUTICALS INC $ Position$73,621,831 % Position5.00% $ Change-1.00% # Change0.00%
Stck TickerN5749R100 Stock NameMERUS N V $ Position$74,744,372 % Position5.00% $ Change-7.00% # Change-29.00%
Stck Ticker26818M108 Stock NameDYNE THERAPEUTICS INC $ Position$76,717,390 % Position5.00% $ Change24.00% # Change0.00%
Stck TickerN69605108 Stock NamePHARVARIS N V $ Position$63,837,393 % Position4.00% $ Change-19.00% # Change0.00%
Stck Ticker00773J202 Stock NameSPYRE THERAPEUTICS INC $ Position$63,134,882 % Position4.00% $ Change-23.00% # Change24.00%
Stck Ticker92790C104 Stock NameVIRIDIAN THERAPEUTICS INC $ Position$50,513,550 % Position3.00% $ Change-26.00% # Change0.00%

Brochure Summary

Overview

A. VR Adviser, LLC (“VRA” or the “Registrant”), a Delaware limited liability company, is a registered investment adviser with the U.S. Securities and Exchange Commission (“SEC”) pursuant to the Investment Advisers Act of 1940 (the “Adviser Act”). It was established in 2013 and is located in New York and California. VRA serves as an investment adviser to pooled investment vehicles (each, a “Fund” or a “Client”)1, and an affiliate of VRA serves as the general partner (or similar managing body) of each Fund. VR Management, LLC (“VRM”), a Delaware limited liability company, is the sole owner of VRA. Bong Y. Koh and Bryan E. Roberts own VRM. VRM has established a committee to govern the affairs of VRA. That committee is overseen by Dr. Koh, Dr. Roberts, and Nimish P. Shah. Mr. Shah is an employee of VRA and is a Member and Director of the General Partners of the Funds. B. VRA provides discretionary investment advisory services solely to Funds. The Venrock Healthcare Capital Partners line of funds (the “VHCP Funds”) focus on long‐term investment opportunities in small capitalization public companies and late‐stage private companies across all sectors in the healthcare and life sciences industry, with a current emphasis on biopharmaceuticals. Venrock Opportunities Fund, L.P. (the “Opportunities Fund”) focuses on later‐stage follow‐on investment opportunities in a subset of the public and private portfolio companies, and former portfolio companies, of other VRA‐affiliated or VRM‐affiliated investment funds. The Firm seeks to apply a value‐driven approach to identify investment opportunities and to apply a primary‐sourced, bottom‐ up, venture capital‐like approach in analyzing company specific opportunities for the Funds. VRA
is affiliated with and serves as manager of entities that serve as the general partners to each of the Funds (each, a “General Partner” and, collectively, the “General Partners”, and together with VRA, the “Firm”), and each of the Funds is controlled by its respective General Partner. The following is a list of each of the General Partners, each of which is an affiliated investment adviser of VRA: General Partners:  VHCP Management, LLC  VHCP Management II, LLC  VHCP Management III, LLC  VHCP Management EG, LLC  Venrock Opportunities Management, LLC C. The investment focus and risks of the Funds are more particularly described in each Fund’s offering and governing documents. The governing documents of the applicable Fund and its offering documents set forth the Fund’s specific guidelines. These guidelines may provide for limits on the 1 “Fund” or “Client” means a private investment fund to which VRA provides investment advice and/or invests on a discretionary or nondiscretionary basis. The individuals and other persons that invest in the VRA private investment funds are generally referred to herein as “investors.” Unless otherwise expressly stated herein, the terms “Fund” and “Client” do not include “investors.” size, concentration, geography, type of security and/or terms of the Fund’s investments. The Firm does not tailor its advisory services to individual investors in its Funds. D. The Registrant does not participate in wrap fee programs. E. As of December 31, 2023, the Registrant (together with the General Partners) manages $2,891,501,332 in Client regulatory assets on a discretionary basis (including the net asset value of portfolio securities valued as of December 31, 2023 plus uncalled capital commitments as of December 31, 2023) and no Client assets on a non‐discretionary basis.